|Title||23andMe (and the FDA) |
|Publication Type||Case Study |
|Year of Publication||2014 |
|Authors||Funke, MB, Boxall, SF, Funke, MB, Myers, GA, Potthast, A |
|Date Published||09/2014 |
|Publisher||Association for Practical and Professional Ethics |
|Publication Language||English |
|Abstract||Genetic testing allows us to discover more and more about ourselves, sometimes more information than we really want ot know. Take, for instance, the tests provided by Silicon Valley-based tech company, 23andMe. This company has made news in the past year because of its direct-to-consumer (DTC) genetic testing, which it marketed as able to predict gene variants “linked to traits ranging from ancestry and earwax to warfarin sensitivity and Alzheimer’s disease.” The company came under pressure from the Food and Drug Administration (FDA), and was ordered on November 22,2013, to stop some of its marketing because of concerns about the reliabilityand applications of the information the company provided. The company since complied with the demands of the FDA and has been permitted to continue marketing its product. But the concerns still persist about the propriety of using such easily-accessible genetic testing to learn more about one’s genetic history and propensities.
|Notes||Case from the 2014 Regional Ethics Bowl. Copyright 2014, Association for Practical and Professional Ethics.
|Audience Level||Undergraduate |